HS-IRBs News August 2012

Health Sciences and Minimal Risk IRBs, IRB News / Volume 4, Number 8, August 2012

HS-IRBs Office Closed September 3rd

The HS-IRBs office will be closed for the Labor Day holiday on Monday, September 3rd. The ARROW helpline also will not be staffed on September 3rd.

New: Responsibilities for Study Teams When IRB Oversight Is Deferred

A new document has been added to the Multisite Research page on the HS-IRBs website that describes study team responsibilities for studies for which IRB oversight has been deferred to a non-UW-Madison IRB. Although such studies are overseen by a non-UW-Madison IRB, study teams still must follow applicable UW-Madison requirements, including:

  • Following the requirements of UW-Madison ancillary committees (e.g., conflict of interest committee) as applicable
  • Reporting funding changes to the IRB of record and providing Research and Sponsored Programs (RSP) with documentation that a study has been deferred to a non-UW-Madison IRB, if requested by RSP
  • Potential unanticipated problems, serious adverse events, or noncompliance that occur at UW-Madison or UW Health sites must be reported to the Health Sciences IRBs in addition to the IRB of record

Please see Study Team Responsibilities When IRB Oversight Is Ceded to an External IRB for the complete list of study team responsibilities.

New Guidance: Timeframe for Submission of Changes of Protocol to the IRB

Because many study teams were not aware of the institutional policy that requires submission of changes of protocol from external sponsors to the IRB within 60 days of their receipt, the HS IRBs have issued the guidance document, Timeframe for Submission of Changes of Protocol to the IRB. This document describes when changes of protocol should be submitted to the IRB and the mechanisms for submission to the IRB if the change is the result of new information or was implemented prior to IRB approval in order to eliminate an apparent immediate hazard to subjects.

New: Who to Contact with Reportable Event Questions

Jessie Johnson is now serving as the IRB lead staff reviewer for reportable events. Study teams with questions about reportable events (e.g., noncompliance, new information reports, unanticipated problems) should contact Jessie directly rather than relying on the HS-IRBs general point of contact system.  Jessie can be reached at 263-0385 and jjohnson@medicine.wisc.edu.

New Guidance: Drug Shortages and Substitutions That Occur During the Conduct of Research Studies

The HS-IRBs have issued new guidance regarding IRB issues related to drug shortages or substitutions that can occur during a research study. Whether the IRB needs to be informed of the drug shortage or substitution depends on whether sites under UW-Madison purview will be affected. If UW-Madison sites are affected, the guidance document describes how to report this information to the IRB. Please see Guidance Regarding Drug Shortages and Substitutions that Occur During the Conduct of Research Studies for additional information.


The SBS and ED IRBs are now piloting ARROW with a small number of study teams. Beginning October 1st, all study teams submitting to the SBS and ED IRBs will need to submit their applications through ARROW. No ARROW applications - other than from the pilot group - will be accepted by the SBS and ED IRBs prior to October 1st.

The SBS and EDIRBs also will have their own ARROW helpline and email address separate from the HS-IRBs helpline. For questions about SBS or ED IRB submissions in ARROW, please contact their helpline at 608-890-4898 or arrow-help@mailplus.wisc.edu.

Reminders about the Human Subjects Research Training Requirement

The HS-IRBs office has recently several questions about the human subjects research training requirement. The requirement for all study team members to complete human subjects research training has been in place since 2005 and has been part of the Summary of Investigator Responsibilities for at least as long. The requirement to check training in ARROW prior to submitting personnel changes and initial review applications is recent, but the requirement to have complete and current training is not.

Please see the Training & Education page for information on training requirements and links to the CITI module.

Revised Guidelines for Deferring IRB Review

The HS-IRBs guidelines for deferring IRB review have been revised to clarify several points, including when the HS-IRBs will not defer IRB review as well as what study teams need to do before submitting a deferral request. The guidelines also now include a new 2 month deadline for developing IRB deferral agreements from the date a deferral request is received. Please see Guidelines for Ceding IRB Review to an External IRB for more information. If you have questions about a deferral request, please contact Carol Pech or Molly Lumley.

Genetic Information and Nondiscrimination Act (GINA) Guidance

In 2008 a federal law called GINA was implemented. This law prohibits discrimination in health coverage and employment based on genetic information, but has some limits. Studies that involve genetic analysis should include language about GINA and its protections and limitations in relevant consent forms. The HS IRBs posted Genetic Information and Nondiscrimination Act (GINA) Guidance that explains GINA and includes required consent form language for studies that involve genetic research.

Information previously provided on this page has been relocated to our new IRB website.

Please visit this page for information about connecting with the IRBs.

Keywords:newsletter, oversight, deferred, multisite, deferring, GINA, drug shortages, reportable events   Doc ID:20451
Owner:Carol P.Group:Health Sciences IRBs
Created:2011-09-27 13:07 CSTUpdated:2015-06-09 15:14 CST
Sites:Health Sciences IRBs
Feedback:  0   0